DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

Information source: Takeda
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: H. Pylori Infection

Intervention: TAK-438 (Drug); Lansoprazole (Drug); Amoxicillin (Drug); Clarithromycin (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Takeda

Official(s) and/or principal investigator(s):
Senior Manager, Study Director, Affiliation: Takeda

Summary

The purpose of this study is to confirm the efficacy of triple therapy with TAK-438, Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to triple therapy with Lansoprazole, Amoxicillin and Clarithromycin in H. pylori-positive patients with scarred gastric or duodenal ulcers.

Clinical Details

Official title: A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the First Line Eradication of H.Pylori

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: H. pylori eradication rate 4 weeks after completion of first-line therapy

Secondary outcome: H. pylori eradication rate 4 weeks after completion of second-line therapy

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Participants must be H. pylori-positive patients at baseline (Visit 1) 2. Participants must be endoscopically confirmed to have scarred gastric ulcer or duodenal ulcer at baseline (Visit 1). However, if a history of ulcers is confirmed by the medical interview or previous medical record, Participants whose gastric ulcer scar or duodenal ulcer scar has disappeared may be included in the study. 3. Outpatient (including inpatient for examination) Exclusion Criteria: 1. Participants who have received H. pylori eradication treatment 2. Participants who have either acute upper gastrointestinal bleeding, gastric ulcer [mucosal defect (with white coating including clot adherence) of 3 mm or larger in size], duodenal ulcer [mucosal defect (with white coating including clot adherence) of 3 mm or larger in size], acute gastric mucosal lesion (AGML), or acute duodenal mucosal lesion (ADML) on endoscopic examination at baseline (Visit 1). However, participants with gastric erosion or duodenal erosion may be included in the study. 3. Participants who have received or who are scheduled to undergo surgery which affects gastric acid secretion (ex, resection of upper gastrointestinal tract, vagotomy, etc) 4. Participants who cannot be treated with medicinal treatment (ex, perforation, pyloric stenosis or large hemorrhage, etc) 5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders 6. Participants with hepatic or renal impairment receiving treatment with colchicines 7. Participants who have a history of hypersensitivity or allergy to TAK-438 (including its excipients), PPIs, penicillin antibiotics, macrolide antibiotics, or antitrichomonal agents 8. Participants with infectious mononucleosis 9. Participants with an organic disease of the brain or spinal cord

Locations and Contacts

Abiko-shi, Chiba, Japan

Kashiwa-shi, Chiba, Japan

Fukui-shi, Fukui, Japan

Fukuoka-shi, Fukuoka, Japan

Ishikari-shi, Hokkaido, Japan

Sapporo-shi, Hokkaido, Japan

Kobe-shi, Hyogo, Japan

Nishinomiya-shi, Hyogo, Japan

Marugame-shi, Kagawa, Japan

Takamatsu-shi, Kagawa, Japan

Kagoshima-shi, Kagoshima, Japan

Ebina-shi, Kanagawa, Japan

Yokohama-shi, Kanagawa, Japan

Yatsushiro-shi, Kumamoto, Japan

Kyoto-shi, Kyoto, Japan

Oita-shi, Oita, Japan

Hirakata-shi, Osaka, Japan

Osaka-shi, Osaka, Japan

Sakai-shi, Osaka, Japan

Suita-shi, Osaka, Japan

Takatsuki-shi, Osaka, Japan

Toyonaka-shi, Osaka, Japan

Saga-shi, Saga, Japan

Kumagaya-shi, Saitama, Japan

Tokorozawa-shi, Saitama, Japan

Shizuoka-shi, Shizuoka, Japan

Adachi-ku, Tokyo, Japan

Chiyoda-ku, Tokyo, Japan

Hachioji-shi, Tokyo, Japan

Kokubunji-shi, Tokyo, Japan

Nishi-tokyo-shi, Tokyo, Japan

Oota-ku, Tokyo, Japan

Ota-ku, Tokyo, Japan

Setagaya-ku, Tokyo, Japan

Shibuya-ku, Tokyo, Japan

Additional Information

Starting date: January 2012
Last updated: November 2, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017